Andromeda Biotech Announces First Patient Dosed In Extension Study To Its Phase 3 Clinical Trial DIA-AID 2 In Patients With Type 1 Diabetes

Published: Dec 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

YAVNE, Israel, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. today announces that the first patient was dosed with DiaPep277® for the treatment of type 1 diabetes in its Extension Study to the Phase 3 Clinical Trial DIA-AID 2.

Help employers find you! Check out all the jobs and post your resume.

Back to news